Curanex Pharmaceuticals Inc Increase (Decrease) in Accounts Payable
Curanex Pharmaceuticals Inc (CURX) reported Increase (Decrease) in Accounts Payable of -$2.27 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- Curanex Pharmaceuticals Inc increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$8.25K.
- Curanex Pharmaceuticals Inc increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $5.98K, a 95.06% decline year-over-year.
- Curanex Pharmaceuticals Inc increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$112.06K.
- Curanex Pharmaceuticals Inc increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $114.22K.
- Curanex Pharmaceuticals Inc increase (decrease) in accounts payable for fiscal 2025 was -$2.57K, a 151.48% decline from fiscal 2024.
- Curanex Pharmaceuticals Inc increase (decrease) in accounts payable for fiscal 2024 was $5.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$2.27K 10-Q · filed 2026-08-14 | -$114.33K derived: sum of 3 quarters · filed 2026-08-14 | -$115.00 derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.98K 10-Q · filed 2026-05-14 | -$106.08K derived: sum of 2 quarters · filed 2026-05-14 | $8.13K derived: sum of 3 quarters · filed 2026-05-14 | -$117.65K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$112.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.16K derived: sum of 2 quarters · filed 2026-03-30 | -$123.63K derived: sum of 3 quarters · filed 2026-08-14 | -$2.57K 10-K · filed 2026-03-30 |
| 2025-09-30 | $114.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$11.57K derived: sum of 2 quarters · filed 2026-08-14 | $109.49K 10-Q · filed 2025-11-17 | $109.49K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$125.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$4.73K 10-Q · filed 2026-08-14 | -$4.73K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-03-31 | $121.06K 10-Q · filed 2026-05-14 | $121.06K derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.00K 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $5.00K 10-Q · filed 2025-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |